The rupee has declined sharply along with other currencies as the dollar has strengthened after Donald Trump took office as ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

One of Monte Rosa's main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders.

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

India's future is being shaped by a new wave of innovative companies revolutionizing industries through technology, ...

Investors were feeling zen on Wednesday, with no major news about Donald Trump's tariffs to worry about ahead of the monthly ...

GigaCloud shows impressive Q3 results, backed by insider buying. Find out why GCT stock remains a buy despite procurement and ...

Our calculations are based on comprehensive, delayed quotes. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all ...

Indian benchmark equity indices reduced their initial gains and were in negative territory on Thursday, influenced by declines in major stocks such as HDFC Bank, ITC, and M&M. This comes as investors ...

Alembic Pharma’s revenue missed our estimates ... and muted growth in the domestic market. Currently, the stock is trading at PE multiple of 21.8x/16.6x based on FY26E/FY27E EPS, respectively.

Amidst a backdrop of fluctuating global markets, where U.S. corporate earnings and AI competition fears have left stocks mostly lower, investors are keenly observing potential opportunities in various ...